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TO THE EDITOR
Atopic dermatitis (AD) is a chronic
allergic disease in skin with severe
irritation and inflammation, and most
patients with AD show elevated plasma
levels of IgE against large numbers of
allergens. It is known that IgE is involved
in type I allergy, which is an immediate
hypersensitivity through mast cells with
IgE. However, it is not clear how IgE
affects chronic allergic diseases such
as AD. Anti-IgE antibody (omalizumab)
has been shown to improve symptoms
in not only allergic rhinitis, which is a
typical type I allergy disease, but also
AD and chronic asthma, which are chronic
allergic diseases (Sheinkopf et al.,
2008). We focused on elucidating the
mechanism for IgE-mediated chronic
inflammation to find and establish a
original treatment for chronic allergic
diseases.
In 2,4,6-trinitrophenol-specific IgE
transgenic mice (TNP-IgE Tg mice), a
single subcutaneous injection of a
multivalent antigen such as TNP-con-
jugated ovalbumin (TNP11-OVA) to the
ear induces tri-phase ear swelling (Mat-
suoka et al., 1999; Sato et al., 2003).
The immediate-phase (within 1 hour
after antigen challenge) and late-phase
(within 6–10 hours after antigen chal-
lenge) ear swelling are typical responses
of type I allergy, whereas the third-
phase ear swelling (began 2 days later
and peaked on days 3–4 after antigen
challenge) especially reflects chronic
IgE-mediated severe inflammation, which
is induced by the multivalent antigen
(Sato et al., 2003). In the histological
change of the third-phase ear swelling,
massive infiltration of inflammatory cells
such as eosinophils, neutrophils, and
hyperplastic epidermis with hyperker-
atosis were observed. Anti-histamine
drugs did not show any significant effect
on the third-phase swelling, whereas
Cyclosporine A inhibited swelling and
cellular infiltration (Sato et al., 2003).
Moreover, we showed that a topical
steroid strongly inhibited swelling and
cellular infiltration (Supplementary
Figure S1 online). The third-phase ear
swelling in TNP-IgE Tg mice has hall-
marks of chronic allergic inflammation
in AD at both points of IgE-mediated
intense chronic inflammation and effects
of therapeutic drugs.
To identify molecules that are
responsible for IgE-mediated chronic
inflammation, we investigated the
gene expression profiles of antigen-
administered ears in TNP-IgE Tg mice
by Affymetrix GeneChip analysis (Santa
Clara, CA). The thickness of TNP11-
OVA-administered ears 24 hours after
antigen challenge (just before the third-
phase ear swelling) has the same degree
as that of OVA-administered (control)
Table 1. Genes listed according to the magnitude of the difference
between TNP11-OVA and OVA in average difference, which refers to the
fold value
Average difference
Genbank
accession no. TNP11-OVA OVA Fold Description
NM_010101 44.8 18.1 2.48 Sphingosine-1-phosphate receptor 3 (S1pr3)
L07379 24.8 13.0 1.91 Growth hormone–releasing hormone receptor
(GHRHR)
NM_013596 45.7 24.4 1.87 Melanocortin 5 receptor (Mc5r)
NM_009219 38.3 24.2 1.58 Somatostatin receptor 4 (Sstr4)
NM_010340 87.7 55.8 1.57 G protein–coupled receptor 50 (Gpr50)
NM_008559 33.1 21.2 1.56 Melanocortin 1 receptor (Mc1r)
NM_010934 47.6 33.1 1.44 Neuropeptide Y receptor Y1 (Npy1r)
NM_015738 47.4 34.3 1.38 Galanin receptor 3 (Galr3)
AF363723 48.7 38.7 1.26 Frizzled 2 (Fzd2)
Abbreviation: TNP11-OVA, 2,4,6-trinitrophenol-conjugated ovalbumin.
Four mice were used in each group for GeneChip analysis. The right and left ears were pooled in each
group (TNP11-OVA-injected ears or OVA-injected ears) and homogenized in TRIzol reagent
(Invitrogen, Carlsbad, CA) for total RNA preparation, as mentioned in the manufacturer’s manuals.
We used the GeneChip Murine Genome U74 Set arrays, which contain 36,900 mouse genes
from Affymetrix (Santa Clara, CA). RNA transcription to complementary DNA, biotinylation to
complementary RNA, fragmentation, hybridization to the chip, and chip analysis using the HP Gene
Array Scanner were performed according to the manufacturer’s manual.
Abbreviations: a-MSH, a-melanocyte-stimulating hormone; AD, atopic dermatitis; GPCR, G
protein–coupled receptors; MC-R, melanocortin receptor; NDP-a-MSH, [Nle4, D-Phe7]-a-MSH; TNP-IgE
Tg mice, 2,4,6-trinitrophenol-specific IgE transgenic mice; TNP11-OVA, TNP-conjugated ovalbumin
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ears (Sato et al., 2003). The histological
inflammatory change was not observed
in both ears; however, the TNP11-OVA-
administered ears 24 hours after antigen
challenge should change the expression
of some genes, which may be respon-
sible for inducing the third-phase in-
flammation. It is practicable to compare
these gene expression profiles between
the TNP11-OVA-administered and con-
trol ears within 24 hours after antigen
challenge without the influence of
inflammatory cells. We compared these
gene expression profiles and found
genes with different expression pat-
terns. We selected genes that were
expressed at higher levels in TNP11-
OVA-administered ears than in control
ears. Moreover, we focused on G
protein–coupled receptors (GPCR),
which have homology to those of hu-
mans. After these screening steps, we
finally selected nine genes (Table 1). In
this list, Mc1r and Mc5r, which are
melanocortin receptors (MC-Rs), are
expressed in both skin and immuno-
cytes. Mc1r, Mc3r, Mc4r, and Mc5r
have a common ligand, a-melanocyte-
stimulating hormone (a-MSH), which
has an anti-inflammatory effect on
inflammatory animal models such as
contact dermatitis (Grabbe et al., 1996;
Brzoska et al., 2008). However, the
mechanism of the anti-inflammatory
effect of a-MSH is not clear because
MC-Rs are widely distributed to various
tissues, and selective agonists for each
MC-Rs do not exist yet. To investigate
the involvement of Mc1r and Mc5r
in IgE-mediated chronic inflammation,
we assessed the effect of a-MSH and
the stable analog peptide [Nle4, D-
Phe7]-a-MSH (NDP-a-MSH), which have
several times higher agonist activity for
Mc1r and Mc5r than a-MSH (Haskell-
Luevano et al., 2001) on the third-phase
ear swelling in TNP-IgE Tg mice.
a-MSH and NDP-a-MSH suppressed
the antigen-induced ear swelling in
TNP-IgE Tg mice (Figure 1a). In particu-
lar, NDP-a-MSH significantly suppressed
the third-phase ear swelling (31%) in-
hibitory rate in the area under the curve
(ear thickness ( 0.01 mm) time (days
2–5)). In addition, a-MSH and predni-
solone marginally suppressed the im-
mediate-phase and third-phase ear
swelling (21% and 20%, respectively,
Figure 1b). a-MSH and NDP-a-MSH
decreased to the nanomolar range in
plasma within 2 hours after intravenous
administration (data not shown). There-
fore, if the agonists for Mc1r and Mc5r
constantly exist with high concentration
in plasma, they may show stronger
inhibitory effects. Artuc et al. (2006)
showed that human mast cells generate
and secrete immunoreactive amounts
of a-MSH, and that the generation and
secretion of a-MSH were augmented by
stimulation of the mast cells with an
anti-IgE antibody (Artuc et al., 2006).
Saline/saline (negative control)
α-MSH/TNP11-OVA
NDP-α-MSH/TNP11-OVA
Prednisolone/TNP11-OVA
Saline/TNP11-OVA (positive control)
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Figure 1. Inhibitory effects of a-melanocyte-stimulating hormone (a-MSH) and [Nle4, D-Phe7]-a-MSH
(NDP-a-MSH) on the tri-phase ear swelling in 2,4,6-trinitrophenol-specific IgE transgenic (TNP-IgE Tg)
mice. (a) The ears of TNP-IgE Tg mice were subcutaneously challenged with 1 mg TNP-conjugated
ovalbumin (TNP11-OVA). a-MSH, NDP-a-MSH (150mg per body weight, each), and saline were
intravenously administered 20 minutes before antigen challenge and twice a day from day 1 to 3.
Prednisolone (2 mg kg1) was orally administered with the same protocol. (b) Area under the curve (AUC)
(ear thickness ( 0.01 mm) time (days 2–5)) on the tri-phase ear swelling. ***Po0.001 vs. negative
control by a t-test. #Po0.05 vs. positive control by a Dunnett test. Data are expressed as the mean±SE,
n¼ 4. Ear thickness was measured with a dial thickness gauge (G-1A; Ozaki, Tokyo, Japan).
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TNP11-OVA administration in TNP-IgE
Tg mice may strongly induce the gen-
eration and secretion of a-MSH from
mast cells. In addition, NC/Nga mice,
which develop AD-like dermatitis un-
der conventional conditions, displayed
an increase of the plasma levels of a-
MSH and an increase of the expression
of Mc1r and Mc5r in skin (Hiramoto
et al., 2009). This report in NC/Nga
mice indicated a similar result to ours,
which is an increase of the expression
of Mc1r and Mc5r on the ears in TNP-
IgE Tg mice after TNP11-OVA adminis-
tration.
In conclusion, we identified the nine
GPCR genes that are highly expressed
just before IgE-mediated chronic in-
flammation in TNP-IgE Tg mice. The
ligands for MC1R and MC5R showed
inhibitory effects on IgE-mediated
chronic allergic inflammation. This
result indicates that MC1R and MC5R
are involved, at least partially, in the
regulation of IgE-mediated chronic in-
flammation. We previously showed that
basophils are crucially involved in the
third-phase ear swelling in TNP-IgE Tg
mice (Mukai et al., 2005). To our
knowledge, there is no available in-
formation about the expression of Mc1r
and Mc5r on basophils; therefore, we
assume that Mc1r and Mc5r indirectly
inhibit IgE–basophil-mediated chronic
inflammation. Further analysis of the
mechanism of the other candidate genes
could lead to the discovery of unknown
mechanisms of IgE-mediated chronic
allergic inflammation and a therapeutic
target for treating chronic allergic in-
flammation.
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TO THE EDITOR
Psoriatic skin contains more nerve
fibers (Naukkarinen et al., 1989), has
increased levels of sensory nerve–der-
ived calcitonin gene-related peptide
(CGRP) and substance P (SP; Chan
et al., 1997; Jiang et al., 1998), and
psoriasis disease severity can be
exacerbated by stress (Griffiths and
Richards, 2001), possibly by increasing
cutaneous nerve numbers and SP and
CGRP expression (Joachim et al., 2007;
Remrod et al., 2007). The clinical
observation that psoriasis undergoes
remission following loss of innervation,
nerve function, or nervous system
injury (Dewing, 1971; Perlman, 1972;
Farber et al., 1990; Stratigos et al.,
1998; Joseph et al., 2005) further
supports a role for the nervous system
in psoriasis pathogenesis; however, the
Abbreviations: BoNT-A, botulinum neurotoxin A; CGRP, calcitonin gene-related peptide ; DC, dendritic
cell; PASI, psoriasis area and severity index; SP, substance P
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